FDA approves Xpovio (selinexor), new treatment for refractory multiple myeloma
10 Luglio 2019
The FDA has granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory
